|
USP12 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.26565424807268E-14 |
| Normal-vs-Stage2 |
3.6243000045566E-08 |
| Normal-vs-Stage3 |
3.49364981389044E-12 |
| Normal-vs-Stage4 |
3.37080363621567E-11 |
| Stage1-vs-Stage2 |
9.998800E-01 |
| Stage1-vs-Stage3 |
1.121430E-01 |
| Stage1-vs-Stage4 |
1.644770E-01 |
| Stage2-vs-Stage3 |
2.688800E-01 |
| Stage2-vs-Stage4 |
2.697800E-01 |
| Stage3-vs-Stage4 |
8.428800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
6.30299999999639E-05 |
| Normal-vs-Asian |
7.10600023268171E-10 |
| Caucasian-vs-AfricanAmerican |
2.891400E-01 |
| Caucasian-vs-Asian |
7.233400E-01 |
| AfricanAmerican-vs-Asian |
2.386200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.3860028376439E-13 |
| Normal-vs-Female |
1.62525548574877E-12 |
| Male-vs-Female |
5.466200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.09525754921469E-12 |
| Normal-vs-Age(41-60Yrs) |
9.99200722162641E-16 |
| Normal-vs-Age(61-80Yrs) |
7.23254789392058E-12 |
| Normal-vs-Age(81-100Yrs) |
1.676750E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.034400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.444830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.171200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.929400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.742000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.544600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.351900E-02 |
| Classical-VS-Follicular |
4.372800E-01 |
| Classical-VS-Other |
1.263800E-01 |
| Classical-VS-Normal |
4.12449963071992E-10 |
| Tall-VS-Follicular |
1.830580E-01 |
| Tall-VS-Other |
4.767400E-01 |
| Tall-VS-Normal |
2.34410268973306E-11 |
| Follicular-VS-Other |
2.745000E-01 |
| Follicular-VS-Normal |
1.83119963637068E-10 |
| Other-VS-Normal |
1.425410E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.06709974190267E-10 |
| N0-vs-N1 |
5.067600E-01 |
|
|
